---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027545"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T20:57:20.358407+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Q2 net loss narrows to $5.2M; OpRegen phase 2a enrolling, OPC1 IND plan in Q4

## Summary
- Net loss narrowed to $5.2M ($0.03/shr) from $6.8M ($0.04/shr) in Q2 2022.
- Revenue fell to $3.2M from $4.6M YoY, driven by lower Roche collaboration revenue.
- Cash $45.9M; expected to fund operations into Q4 2024.
- OpRegen Phase 2a enrolling; FDA meeting response enables OPC1 delivery device IND amendment in Q4.
- VAC2 Phase 1 topline: five of eight stable disease; three of eight reached 2-year survival.

## SEC filing metadata
- accession: 0001493152-23-027545
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/0001493152-23-027545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027545
- JSON: https://secwatch.observer/filing/0001493152-23-027545.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027545.txt

## Key facts
- Earnings Releases
  Lineage Cell Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $3.2 million.
  - Period: second quarter ended June 30, 2023
  - Revenue: $3.2 million
  - Result: reported results
  source text: revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended June 30, 2023 were $3.2 million, a net decrease of $1.4 million as compared to approximately $4.6 million for the same period in 2022. The decrease was primarily driven by less collaboration and licensing
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000149315223027545/0001493152-23-027545-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.